The latest price target for Health Catalyst (NASDAQ:HCAT) was reported by Cantor Fitzgerald on September 20, 2024. The analyst firm set a price target for $16.00 expecting HCAT to rise to within 12 months (a possible 99.50% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Health Catalyst (NASDAQ:HCAT) was provided by Cantor Fitzgerald, and Health Catalyst reiterated their overweight rating.

The last upgrade for Health Catalyst Inc happened on January 26, 2024 when Guggenheim raised their price target to $14. Guggenheim previously had a neutral for Health Catalyst Inc.

The last downgrade for Health Catalyst Inc happened on April 10, 2024 when Keybanc changed their price target from N/A to N/A for Health Catalyst Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Health Catalyst, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Health Catalyst was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Health Catalyst (HCAT) rating was a reiterated with a price target of $16.00 to $16.00. The current price Health Catalyst (HCAT) is trading at is $8.02, which is out of the analyst’s predicted range.